

Pre-Clinical Early Diagnosis

- Fully compliant with FDA, OECD and SFDA GLP requirements

WuXi Apptec's Safety Evaluation Testing (Suzhou) offers seamless integration with our drug discovery and development services, accelerated timelines for candidate selection, and a cost advantage that yields one of the best values in the industry.

Experienced "Returnees" with average of 15 years of experience working overseas in Big Pharmas and CROs manage study conduct and daily operations.

WuXi AppTec is a global leader in providing discovery, testing and manufacturing services for the pharmaceutical, biotechnology and medical device industries. Research-driven and customer-focused, with operations in China and the U.S., WuXi AppTec offers a broad and integrated portfolio of services designed to assist our customers with cost-effective and efficient outsourcing solutions.

WX
LISTED
NYSE

Early Diagnosis Tests (EDT)

--- Reduce the risks and costs of preclinical safety evaluation by early detection of drug candidates with toxicity potential using our established testing packages.

50 - 70g lead compound synthesized

Genotoxicity in vitro:

- Mini Ames & In vitro micronucleus
- 0.1 g compound

QT prolongation in vitro and in vivo:

- hERG assay & ECG in guinea pigs
- 0.5 g compound

Target organs and dose-limiting toxicities in two species (Dog and Rat):

- 5-14 day repeated dose toxicity & TK studies
- 50 - 65g compound

Draft report available 10-12 weeks from start of synthesis

- Compound synthesis time depends on the steps involved and difficulty of the process

We can customize the package!

